Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1186/S12968-019-0556-1 | ||||
| Año | 2019 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
BackgroundFor two decades, bright-blood late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) has been considered the reference standard for the non-invasive assessment of myocardial viability. While bright-blood LGE can clearly distinguish areas of myocardial infarction from viable myocardium, it often suffers from poor scar-to-blood contrast, making subendocardial scar difficult to detect. Recently, we proposed a novel dark-blood LGE approach that increases scar-to-blood contrast and thereby improves subendocardial scar conspicuity. In the present study we sought to assess the clinical value of this novel approach in a large patient cohort with various non-congenital ischemic and non-ischemic cardiomyopathies on both 1.5T and 3T CMR scanners of different vendors.MethodsThree hundred consecutive patients referred for clinical CMR were randomly assigned to a 1.5T or 3T scanner. An entire short-axis stack and multiple long-axis views were acquired using conventional phase sensitive inversion recovery (PSIR) LGE with TI set to null myocardium (bright-blood) and proposed PSIR LGE with TI set to null blood (dark-blood), in a randomized order. The bright-blood LGE and dark-blood LGE images were separated, anonymized, and interpreted in a random order at different time points by one of five independent observers. Each case was analyzed for the type of scar, per-segment transmurality, papillary muscle enhancement, overall image quality, observer confidence, and presence of right ventricular scar and intraventricular thrombus.ResultsDark-blood LGE detected significantly more cases with ischemic scar compared to conventional bright-blood LGE (97 vs 89, p=0.008), on both 1.5T and 3T, and led to a significantly increased total scar burden (3.32.4 vs 3.0 +/- 2.3 standard AHA segments, p=0.015). Overall image quality significantly improved using dark-blood LGE compared to bright-blood LGE (81.3% vs 74.0% of all segments were of highest diagnostic quality, p=0.006). Furthermore, dark-blood LGE led to significantly higher observer confidence (confident in 84.2% vs 78.4%, p=0.033).Conclusions The improved detection of ischemic scar makes the proposed dark-blood LGE method a valuable diagnostic tool in the non-invasive assessment of myocardial scar. The applicability in routine clinical practice is further strengthened, as the present approach, in contrast to other recently proposed dark- and black-blood LGE techniques, is readily available without the need for scanner adjustments, extensive optimizations, or additional training.
| WOS |
|---|
| Cardiac & Cardiovascular Systems |
| Radiology, Nuclear Medicine & Medical Imaging |
| Cardiac & Cardiovascular System |
| Scopus |
|---|
| Radiology, Nuclear Medicine And Imaging |
| Radiological And Ultrasound Technology |
| Cardiology And Cardiovascular Medicine |
| Family Practice |
| SciELO |
|---|
| Sin Disciplinas |
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Holtackers, Robert J. | Hombre |
Maastricht Univ - Países Bajos
Kings Coll London - Reino Unido Maastricht University - Países Bajos King's College London - Reino Unido Cardiovascular Research Institute Maastricht - Países Bajos St Thomas' Hospital - Reino Unido Universiteit Maastricht - Países Bajos CARIM School for Cardiovascular Disease - Países Bajos Maastricht Universitair Medisch Centrum+ - Países Bajos |
| 2 | Van De Heyning, Caroline M. | Mujer |
Kings Coll London - Reino Unido
St Thomas Hosp - Reino Unido Antwerp Univ Hosp - Bélgica Univ Antwerp - Bélgica King's College London - Reino Unido Guy's and St Thomas' NHS Foundation Trust - Reino Unido Universitair Ziekenhuis Antwerpen - Bélgica Universiteit Antwerpen - Bélgica St Thomas' Hospital - Reino Unido |
| 3 | Nazir, Muhummad Sohaib | - |
Kings Coll London - Reino Unido
St Thomas Hosp - Reino Unido King's College London - Reino Unido Guy's and St Thomas' NHS Foundation Trust - Reino Unido St Thomas' Hospital - Reino Unido |
| 4 | Rashid, Imran | Hombre |
Kings Coll London - Reino Unido
St Thomas Hosp - Reino Unido King's College London - Reino Unido Guy's and St Thomas' NHS Foundation Trust - Reino Unido St Thomas' Hospital - Reino Unido |
| 5 | Ntalas, Ioannis | Hombre |
Kings Coll London - Reino Unido
St Thomas Hosp - Reino Unido King's College London - Reino Unido Guy's and St Thomas' NHS Foundation Trust - Reino Unido St Thomas' Hospital - Reino Unido |
| 6 | Rahman, Haseeb | Hombre |
Kings Coll London - Reino Unido
St Thomas Hosp - Reino Unido King's College London - Reino Unido Guy's and St Thomas' NHS Foundation Trust - Reino Unido St Thomas' Hospital - Reino Unido |
| 7 | Botnar, Reneprime M. | Hombre |
Kings Coll London - Reino Unido
Pontificia Universidad Católica de Chile - Chile King's College London - Reino Unido St Thomas' Hospital - Reino Unido |
| 8 | Chiribiri, Amedeo | Hombre |
Kings Coll London - Reino Unido
King's College London - Reino Unido St Thomas' Hospital - Reino Unido |
| Fuente |
|---|
| FONDECYT |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| Medical Research Council |
| EPSRC |
| UK Medical Research Council |
| British Heart Foundation |
| Engineering and Physical Sciences Research Council |
| Fondo Nacional de Desarrollo CientÃfico, Tecnológico y de Innovación Tecnológica |
| Research Councils UK |
| King's College London |
| FONDECYT N |
| Welcome EPSRC Centre for Medical Engineering |
| Stichting de Weijerhorst |
| NIHR Biomedical Research Centre (BRC) |
| Department of Health through the National Institute for Health Research (NIHR) Healthcare Technology Cooperative for Cardiovascular Diseases at Guy's and St Thomas' NHS Foundation Trust |
| National Institute for Health Research |
| NIHR Imperial Biomedical Research Centre |
| Heart of England NHS Foundation Trust |
| King’s College London |
| Department of Health, Australian Government |
| Guy’s and St Thomas’ NHS Foundation Trust |
| Guy's and St Thomas' NHS Foundation Trust |
| NIHR Bristol Biomedical Research Centre |
| Manchester Biomedical Research Centre |
| EPSRC Centre for Medical Engineering |
| Healthcare Technology Co-operative for Cardiovascular Diseases |
| Department of Health and Social Care |
| Agradecimiento |
|---|
| The authors acknowledge financial support from Stichting de Weijerhorst, the British Heart Foundation (RG/12/1/29262), the EPSRC (EP/P001009/1 and EP/P007619/1), the Welcome EPSRC Centre for Medical Engineering (NS/A000049/1 and WT/203148/Z/16/Z), the UK Medical Research Council (MR/P01979X/1), the FONDECYT No 1161051, the Department of Health through the National Institute for Health Research (NIHR) Healthcare Technology Cooperative for Cardiovascular Diseases at Guy's and St Thomas' NHS Foundation Trust, and the NIHR Biomedical Research Centre (BRC) awarded to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, and/or the Department of Health. |
| The authors acknowledge financial support from Stichting de Weijerhorst, the British Heart Foundation (RG/12/1/29262), the EPSRC (EP/P001009/1 and EP/P007619/1), the Welcome EPSRC Centre for Medical Engineering (NS/ A000049/1 and WT/203148/Z/16/Z), the UK Medical Research Council (MR/ P01979X/1), the FONDECYT N° 1161051, the Department of Health through the National Institute for Health Research (NIHR) Healthcare Technology Co-operative for Cardiovascular Diseases at Guy’s and St Thomas’ NHS Foundation Trust, and the NIHR Biomedical Research Centre (BRC) awarded to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, and/or the Department of Health. |